Literature DB >> 20412370

Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics.

S Wahlin1, Y Floderus, P Stål, P Harper.   

Abstract

OBJECTIVE: To investigate the demographic, clinical, biochemical and genotypic features of patients with erythropoietic protoporphyria (EPP) in a Swedish cohort.
DESIGN: Cross-sectional questionnaire, biochemical and genetic study.
SETTING: Sweden.
SUBJECTS: Fifty-one Swedish individuals known in 2008 to have EPP confirmed by molecular diagnosis. There were no exclusion criteria; all patients were included in the demographic and genetic study. A total of 92% participants completed the questionnaire study and 82% the biochemical study.
RESULTS: The prevalence of EPP was 1 : 180,000. Nine novel ferrochelatase gene mutations were found. The most commonly reported age at onset of symptoms was the first year of life and the mean age at diagnosis was 22 years. Painful photosensitivity was the main symptom. Exogenous factors other than sunlight were frequently reported to cause cutaneous symptoms. One in five patients reported a positive effect of beta-carotene therapy. A marked impact of EPP on quality of life was reported. Women had a significantly lower mean erythrocyte protoporphyrin concentration than men. Of all participants, 84% had insufficient vitamin D concentrations, 44% had below normal serum ferritin or transferrin saturation levels and red cell abnormalities were common.
CONCLUSIONS: The notably delayed diagnosis suggests the need for an increased awareness of EPP. Disturbed erythropoiesis, biochemical signs of iron deficiency and low vitamin D levels are frequent findings in this disease. New and better treatments are needed as current treatment options for symptom amelioration are limited. Vitamin D supplementation should be considered.
© 2010 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20412370     DOI: 10.1111/j.1365-2796.2010.02236.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  15 in total

1.  Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria.

Authors:  John Phillips; Collin Farrell; Yongming Wang; Ashwani K Singal; Karl Anderson; Manisha Balwani; Montgomery Bissell; Herbert Bonkovsky; Toni Seay; Barry Paw; Robert Desnick; Joseph Bloomer
Journal:  Mol Genet Metab       Date:  2018-10-22       Impact factor: 4.797

2.  Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.

Authors:  Manisha Balwani; Hetanshi Naik; Karl E Anderson; D Montgomery Bissell; Joseph Bloomer; Herbert L Bonkovsky; John D Phillips; Jessica R Overbey; Bruce Wang; Ashwani K Singal; Lawrence U Liu; Robert J Desnick
Journal:  JAMA Dermatol       Date:  2017-08-01       Impact factor: 10.282

3.  Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity.

Authors:  Jasmin Barman-Aksoezen; Domenico Girelli; Caterina Aurizi; Xiaoye Schneider-Yin; Natascia Campostrini; Luca Barbieri; Elisabeth I Minder; Gianfranco Biolcati
Journal:  J Inherit Metab Dis       Date:  2017-02-09       Impact factor: 4.982

4.  The incidence of inherited porphyrias in Europe.

Authors:  George Elder; Pauline Harper; Michael Badminton; Sverre Sandberg; Jean-Charles Deybach
Journal:  J Inherit Metab Dis       Date:  2012-11-01       Impact factor: 4.982

5.  Bone mineral density and vitamin D levels in erythropoietic protoporphyria.

Authors:  Gonzalo Allo; Maria del Carmen Garrido-Astray; Manuel Méndez; Rafael Enríquez De Salamanca; Guillermo Martínez; Federico Hawkins
Journal:  Endocrine       Date:  2013-03-28       Impact factor: 3.633

6.  Afamelanotide for Erythropoietic Protoporphyria.

Authors:  Janneke G Langendonk; Manisha Balwani; Karl E Anderson; Herbert L Bonkovsky; Alexander V Anstey; D Montgomery Bissell; Joseph Bloomer; Chris Edwards; Norbert J Neumann; Charles Parker; John D Phillips; Henry W Lim; Iltefat Hamzavi; Jean-Charles Deybach; Raili Kauppinen; Lesley E Rhodes; Jorge Frank; Gillian M Murphy; Francois P J Karstens; Eric J G Sijbrands; Felix W M de Rooij; Mark Lebwohl; Hetanshi Naik; Colin R Goding; J H Paul Wilson; Robert J Desnick
Journal:  N Engl J Med       Date:  2015-07-02       Impact factor: 91.245

Review 7.  Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.

Authors:  Manisha Balwani
Journal:  Mol Genet Metab       Date:  2019-01-24       Impact factor: 4.797

Review 8.  Diagnostic Delay in Erythropoietic Protoporphyria.

Authors:  Sajel M Lala; Hetanshi Naik; Manisha Balwani
Journal:  J Pediatr       Date:  2018-07-02       Impact factor: 4.406

Review 9.  Protoporphyrin IX: the Good, the Bad, and the Ugly.

Authors:  Madhav Sachar; Karl E Anderson; Xiaochao Ma
Journal:  J Pharmacol Exp Ther       Date:  2015-11-20       Impact factor: 4.030

Review 10.  The porphyrias: advances in diagnosis and treatment.

Authors:  Manisha Balwani; Robert J Desnick
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.